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Abstract
Despite the discovery over 60 years ago by Huggins and Hodges [1] that prostate cancers
respond to androgen deprivation therapy, hormone-refractory prostate cancer remains a
major clinical challenge. There is now mounting evidence that solid tumours originate from
undifferentiated stem cell-like cells coexisting within a heterogeneous tumour mass that
drive tumour formation, maintain tumour homeostasis and initiate metastases. This review
focuses upon current evidence for prostate cancer stem cells, addressing the identiﬁcation
and properties of both normal and transformed prostate stem cells.
Copyright  2008 Pathological Society of Great Britain and Ireland. Published by John
Wiley & Sons, Ltd.
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Introduction
Prostate cancer is the most frequently diagnosed can-
cer in men and is excelled only by lung cancer as
the leading cause of cancer-related mortality among
men. Despite recent advances in the detection of early
prostate cancer, there remains little effective therapy
for patients with locally advanced and/or metastatic
disease. The majority of patients with advanced dis-
ease respond initially to androgen ablation therapy,
due to the androgen-dependent nature of the vast
majority of prostate cancer cells. However, with very
high frequency, androgen-independent cancers emerge
and subsequently widespread metastasis occur. Once
patients relapse with hormone-resistant disease, resid-
ual androgens produced by the adrenal glands and
possibly the prostate are thought to restore androgen
receptor (AR) signalling in cells that have become
more sensitive to androgens through ampliﬁcation of
the AR [2], mutations in the AR gene [3], increased
AR expression [4] or alterations in AR corepres-
sor–coactivator function [5]. Moreover, as the major-
ity of human prostate adenocarcinomas have this
mature luminal phenotype, characterized by expression
of cytokeratins 8/18, AR and prostate-speciﬁc antigen
(PSA), the assumption has been that the cell of ori-
gin of prostate cancer is the differentiated secretory
luminal cell.
That hypothesis is based on the observation that
most hormone-refractory tumours continue to express
AR and androgen-regulated genes, such as PSA [6].
However, there is a remarkable degree of pheno-
typic heterogeneity amongst tumour cells, for example,
within metastatic sites [7]. Metastases often include
rare cells that are phenotypically undifferentiated,
expressing prostate basal cell markers, such as cytok-
eratins 5 and 14. This heterogeneity is seen between
different patients as well as at multiple sites within
individual patients. This suggests that the metastasis-
initiating cell may not be derived from the AR+ secre-
tory luminal population. An understanding of the cell
of origin of prostate cancers should be a major focus of
research if we are to develop treatments for, or prevent
the evolution to, androgen-refractory prostate cancer.
Anatomy of the human prostate
The prostate is a complex tubulo-alveolar gland com-
posed of an epithelial parenchyma embedded within a
connective tissue matrix. The epithelial cells are orga-
nized in glands that branch out from the urethra and
terminate in secretory acini.
The prostate gland develops from the urogenital
sinus in response to testosterone stimulation. The
embryonic prostate initially consists of a multilayered
epithelium surrounded by mesenchyma. In a process of
ductal budding, which starts at 10 weeks of gestation,
multiple epithelial outgrowths invade the surrounding
mesenchyma. These epithelial buds form ducts that
elongate and branch out from the urethra and terminate
into acini. From the 20th week of gestation up to
puberty, the immature prostatic acini and ducts are
lined with multiple layers of immature cells that
express cytokeratins of simple and stratiﬁed epithelium
[8]. Postnatal development includes a period of growth
during the ﬁrst year, quiescence during childhood and
further growth with the testosterone surge at puberty.
During puberty, the immature multilayered epithelium
differentiates into a two-layered epithelium consisting
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of peripheral cuboidal basal cells and inner secretory
columnar epithelium [9].
The main cell types discernible within normal,
mature prostatic epithelium are basal, secretory lumi-
nal and neuroendocrine cells. The luminal or glandu-
lar cells constitute the exocrine compartment of the
prostate, secreting PSA and prostatic acid phosphatase
(PAP) into the glandular lumina. They are terminally
differentiated, and represent the major cell type in nor-
mal and hyperplastic epithelium. They express high
levels of the AR [10] and are dependent on andro-
gens for their survival [11]. In contrast, basal cells
are relatively undifferentiated and lack secretory activ-
ity. As their name suggests, basal cells rest on the
basement membrane and morphologically they range
from small ﬂattened to cuboidal cells. They express
low/undetectable levels of AR [12] and are indepen-
dent of androgens for their survival [11]. Basal cells
focally express oestrogen receptor (ER)β and prolif-
erate under oestrogen therapy [13], but this affect on
proliferation is possibly due to ER signalling via the
stroma.
Signiﬁcant populations of neuroendocrine cells also
reside amongst the basal cell compartment. They are
found in the epithelium of the acini and in ducts of
all parts of the gland. The major type of neuroen-
docrine cell contains serotonin and thyroid-stimulating
hormone. Neuroendocrine cells are terminally differ-
entiated, post-mitotic cell types that are androgen-
insensitive [14].
Epithelial stem cells in the normal prostate
Evidence for the existence of a stem cell subpopulation
in the prostate has been accumulating since the 1980s.
Initial experiments in the murine prostate demon-
strated that the adult rodent prostate can undergo
multiple rounds of castration-induced regression and
androgen-induced regeneration [15]. The preferential
survival of the basal cells following androgen ablation
led to the hypothesis that the stem cells reside within
the basal cell layer of the gland [16]. This is supported
by ﬁndings that mice null for the basal cell marker p63
are born without a prostate [17]. By complementing
p63−/− blastocysts with p63+/+ β-galactosidase (β-
gal)-positive ES cells, Signoretti and colleagues [18]
showed that p63 is required for commitment to the
prostate cell lineage and, importantly, secretory cells
of the prostate originate from p63-positive basal pro-
genitor cells. In contrast to these ﬁndings, Cunha and
colleagues [19] observed that fetal urogenital sinus
tissue from p63 null mice can regenerate prostate duc-
tal tissue following implantation in immunodeﬁcient
mice. Regenerated tissue lacked identiﬁable basal cells
but did contain cells that expressed typical luminal
markers. Although this ﬁnding suggests that luminal
cells are not derived from basal cells, an alternative
explanation might be that in the absence of p63 the
prostate does not develop normal stratiﬁed epithelia.
However, a rudimentary epithelium is apparent which
can commit to luminal differentiation, but with loss
of the regenerative population of cells. In support of
this, the embryonic epidermis of p63-null mice under-
goes an unusual process of non-regenerative differen-
tiation [20]. These ﬁndings are supported by culture
experiments, whereby basal cells display differential
capacities for proliferation, representative of highly
regenerative stem cells as well as transient ampli-
fying cells with more limited proliferative potential.
Thus, in vivo, the self-renewing stem cells may act as
a reserve pool for these amplifying cells.
Location of stem cells
In the murine prostate each prostatic duct consists of a
proximal region attached to the urethra, an intermedi-
ate region and a distal tip [21]. Proliferating cells are
located at the tips of the ducts and can undergo sig-
niﬁcant growth when grafted under the renal capsule
in combination with embryonic urogenital sinus mes-
enchyme [22]. Based on this ﬁnding, it was suggested
that prostatic stem cells reside in the distal region [22].
However, Tsujimura and colleagues [23] demonstrated
that the proximal region is enriched in a subpopula-
tion of epithelial cells that are slow-cycling, possess
ah i g hin vitro proliferative potential and can recon-
stitute highly branched glandular ductal structures in
collagen gels. They proposed that prostatic epithelial
stem cells are concentrated in the proximal region of
the ducts and give rise to the proliferating transit-
amplifying cells that migrate distally. The proximal
region is characterized by a thick band of smooth mus-
cle cells that secrete high levels of TGFβ, making it
a possible location for the stem cell niche as this fac-
tor is known to maintain prostate stem cell quiescence
[24]. More recent work in the mouse has concentrated
on identifying stem cells using cell surface markers,
such as Sca-1 [25]. These authors demonstrated that
Sca1+ enriches for a prostate-regenerating cell popu-
lation that is concentrated in the proximal region of
the mouse prostatic duct. However, they also reported
sporadic Sca-1 expression in the distal region of ducts
and regenerating activity could also be attributed to
Sca-1− cells [25].
Stem cells in the human prostate can be identi-
ﬁed and isolated using the cell surface markers inte-
grin α2β1 [26,27] and CD133 [28]. Unlike the previ-
ous studies in murine prostate, α2β1
hi/CD133+ cells
are randomly distributed throughout acini and ductal
regions [26,28], often at the base of budding regions or
branching points. Of relevance to the determination of
lineage(s) is the ﬁnding that cells that are morpholog-
ically and phenotypically intermediate between basal
and luminal cells have been identiﬁed within the nor-
mal prostatic epithelium [29–33]. These observations
demonstrate that basal and luminal cells are linked in
a hierarchical pathway, but to resolve the issue of lin-
eage it will be necessary to track the progeny and dif-
ferentiation of a marked or isolated stem cell — either
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as a clonal regeneration assay (regenerating a culture
from a single cell) or using a transfected marker.
Stem cell niche
Stem cells are generally quiescent and reside in a
specialized cellular location known as a niche. The
niche provides a microenvironment that maintains the
balance between quiescence and self-renewal of the
stem cell population. The mechanism by which the
microenvironment controls quiescence and activation
of the primitive phenotype is poorly understood, par-
ticularly for adult tissue. The most well-deﬁned stud-
ies of the niche are provided by Drosophila and
Caenorhabditis elegans germ stem cell niches. Molec-
ular analysis has revealed that these niches are gen-
erally regulated by extracellular matrix interactions
and growth factors. In Drosophila ovary and testis,
stem cells are in close contact with the other cells of
the niche. These neighbouring cells anchor the stem
cells, maintaining quiescence and allowing establish-
ment of asymmetric division. Spindle orientation dic-
tates asymmetrical division in the male Drosophila
germ stem cell [34,35]. The mother centrosome within
the stem cell is anchored to the hub cells of the
niche. This ensures that the mother centrosome is
inherited by the stem cell, whilst the daughter cen-
trosome is passed to the differentiating gonialblast.
Anchoring the stem cell ensures that the daughter cells
move into different microenvironments and are thus
exposed to different extrinsic signals that direct cell
fate.
In the adult prostate, we have shown that the
epithelial stem cells sit on the basement membrane,
where they are anchored by high expression of integrin
α2β1 (Figure 1) [26]. β1 integrins provide important
signals for many niches. In Drosophila they are
required for stem cell maintenance and positioning
of the niche [36] and in the mammary system β1
integrin is required to maintain a functional stem cell
population and establish asymmetric division [37].
Prostate homeostasis is maintained as a result of
androgenic regulation of stromal–epithelial interac-
tions. Epithelial cell determination as well as differ-
entiation is controlled by an inductive mesenchymal
signal [38]. For example, embryonic rat and mouse
Figure 1. A frozen section of prostate labelled with α2-integrin
antibody, directly labelled with ﬂuorescein isothiocyanate
(FITC) and viewed by confocal microscopy. Reproduced with
permission from [26]
prostatic mesenchyme can direct human embryonic
stem cells to generate human prostatic epithelial tis-
sues [39,40]. In vitro experiments have also indicated
the importance of adult stroma to direct the growth of
adult prostatic structures [41].
The pathways controlling stem cell fate in
Drosophila include JAK–STAT, BMP/TGFβ, Hedge-
hog and Piwi. These signals are activated by the hub
cells of the niche, highlighting the importance of niche
support cells [42,43]. Asymmetrical division of the
stem cells ensures that the daughter cells move out
of the niche. The resultant loss of signal from the hub
cells results in differentiation [44]. In the haematopoi-
etic system Hedgehog, Wnt, Notch and TGFβ1–BMP
signalling all have important functions in stem cell
control, whilst the skin stem cell niche is controlled by
Wnt and TGFβ1–BMP signalling [45]. In the prostate,
Notch 1 signalling controls normal cell proliferation
and differentiation, but the involvement of stem cells
has not been deﬁned, although progenitor cells are
negatively controlled by Notch [46]. High levels of
TGFβ1 signalling are present in quiescent proximal
regions of mouse prostatic ducts [24] and it is postu-
lated that this signalling is responsible for a quiescent
stem cell niche (Figure 2).
Cancer and the niche
The niche can respond dynamically to physiologi-
cal requirements, which is central to homeostasis. An
imbalance in the control of the niche may contribute
Figure 2. A colony derived from a single PKH26-labelled
prostate epithelial cell at day 4. As the cells divide, the intensity
of ﬂuorescence is diluted. Note the quiescent, bright cells at
the edge of the colony
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to disease. For example, disruption of the cellular
control of asymmetrical division leads to the forma-
tion of tumours in Drosophila (reviewed in [47]).
In the prostate, gene expression proﬁling of normal
α2β1
hi/CD133+ cells and their malignant equivalent
shows an up-regulation of focal adhesion pathways
and extracellular matrix–integrin signalling in can-
cer stem cells, indicating that cancer stem cells may
respond differently to, or alter, their niche. In partic-
ular, integrin αv, collagen type 5 α1 chains, laminin
α1 and laminin γ1 chains are all over-expressed in
cancer stem cells [48]. The biological consequence
of these changes is unknown, but it can be postu-
lated that they will directly impact on the control
of the stem cell niche over stem cell function. Gene
expression proﬁling further indicated that components
of the JAK–STAT pathway are over-expressed in
prostate cancer stem cells [48]. Over-expression of the
JAK–STAT ligand (unpaired) in the Drosophila ovar-
ian niche increases the divisional rate of stem cells and
results in the occasional formation of germline stem
cell tumours [49]. Similarly, components of Wnt sig-
nalling are over-represented in cancer stem cells and
there is a large amount of evidence to connect Wnt sig-
nalling with both stemness and cancer in other tissues
(reviewed in [50]).
In the prostate there is evidence that cancer-
associated stroma plays an important role in cancer
initiation. Work by Chung [51], Olumi [52] and co-
workers has shown that stroma derived from prostate
tumours induces tumourigenicity of non-malignant
epithelia. Further analysis of cancer-derived stroma
has indicated that secreted frizzled-related protein
1 (SFRP1), TGFβ1 and stromal cell-derived fac-
tor 1 (SDF-1/CXCL12) are all candidate molecules
for inducing tumourigenicity in prostate. Interest-
ingly, SFRP1 is an inhibitor of the Wnt path-
way. SDF-1 is a cell adhesion molecule and a
member of the immunoglobulin superfamily. The
receptor for SDF-1 (SDFR-1, or neuroplastin) is
expressed by prostate stem cells [48], indicating that
in cancer SDF-1 signalling pathways are likely to
be important. SDF-1–CXCR4 signalling can induce
cancer-like behaviour, such as activation of anti-
apoptotic pathways [53], motility, homing and adhe-
sion during embryogenesis, organogenesis and metas-
tasis (reviewed in [54]). SDFR-1–CXCR4 is important
for haematopoietic stem cell trafﬁcking and homing
to the niche [55]. SDF-1 can signal through ERK1/2
pathways, PI3K-activated PKC pathway, JAK–STAT
pathways and NFκB [56]. One of the end points of this
signalling is the phosphorylation of focal adhesions
proteins [57]. Intriguingly, focal adhesion, JAK–STAT
and NFκB are key processes associated with a prostate
cancer stem cell phenotype [48].
Cancer stem cells
The cellular origins of prostate cancer are still con-
troversial. It has been suggested that prostate cancers
arise from the terminally differentiated luminal cells
[58,59] because the bulk population of tumour cells,
in the most common form of prostate cancer, express
luminal cell-speciﬁc markers (cytokeratins 8, 18 AR,
PSA and PAP), but lack expression of basal cell mark-
ers, such as p63. Moreover, cells that solely express
basal cell markers, such as CK5 and CK14, are rarely
observed. This has led some to speculate that prostate
cancers are derived from intermediate progenitors that
have acquired the ability to self-renew [60].
However, several lines of evidence support the
proposal that prostate cancer stem cells arise from
normal stem cells. Advanced prostate cancers are
androgen-independent and basal cells (phenotypically)
can be identiﬁed from the majority of metastases [61].
Craft and colleagues [62] also showed that advanced
androgen-independent tumours arise from the clonal
expansion of AR− cells which are present at a fre-
quency of 1 per 105–106 AR+ cells. More recent
work from our laboratory compared isolated popu-
lations from primary prostate cancers for clonogenic
potential. We found that only the most primitive cells
(α2β1
hi/CD133+/CD44+), which were identical phe-
notypically to normal prostate stem cells, could self-
renew in vitro [63]. Moreover, under differentiating
conditions, AR+/PAP+/CK18+ luminal cells could
be identiﬁed in these cultures, suggesting that they
were derived from the more primitive population. In
support of this ﬁnding, the CD44+ population from
xenograft tumours and cell lines has enhanced prolif-
erative potential and tumour-initiating ability in vivo
compared to CD44− cells [64]. The CD44+ cells are
likewise AR− and express higher mRNA levels of
stemness genes, such as OCT3/4 and BMI 1.U s i n g
clonally-derived human prostate cancer epithelial cells
expressing human telomerase reverse transcriptase
(hTERT), Gu and co-workers [65] demonstrated that
these lines could regenerate tumours in mice that
resembled the original patient tumour with respect to
Gleason score. The tumours contained luminal, basal
and neuroendocrine cells, implying that the clone of
origin could differentiate into the epithelial cells lin-
eages of the prostate. In this case, the tumour-initiating
cell was AR− and p63− and expressed the stem cell
genes Oct-4, Nanog, Sox2, nestin, CD44, CD133 and
c-kit. Moreover, Sca-1-sorted cells, enriched for cells
with prostate-regenerating activity, showed evidence
of basal and luminal lineage.
A genetic hallmark of leukemic disease is expres-
sion of speciﬁc fusion proteins, such as the BCR–ABL
chimeric protein found in CML patients [66]. As this
fusion protein can be found in several blood lineages,
it is highly probable that the disease originates in the
haematopoietic stem cell (HSC). This has been backed
up by numerous studies which show that only the HSC
phenotype (CD34+,C D 3 8 −) can transfer disease in
non-obese diabetic/severe combined immunodeﬁcient
(NOD/SCID) mice [67].
A recurrent genomic alteration in prostate can-
cer is the expression of TMPRSS2-ETS fusion genes
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[68], with TMPRSS2–ERG being the most frequently
detected [69]. The presence of the fusion is associated
with PSA biochemical failure [69] and occurs with a
frequency of approximately 50% [70]. Identiﬁcation
of the TMPRSS2–ETS fusion gene in approximately
20% of PIN lesions suggests that it is an early event
in prostate tumourigenesis [71] and our recent ﬁndings
that TMPRSS2–ERG is expressed in α2β1
hi/CD133+
cells from prostate tumours [48] supports the hypoth-
esis that the cell of origin of prostate cancer is a
stem cell. Intriguingly, expression of the fusion gene
is androgen-regulated, yet cancer stem cells are AR−.
A recent ﬁnding that TMPRSS2–ETS gene rearrange-
ments are observed in androgen-independent disease
[72] and that TMPRSS2–ERG expression can be reg-
ulated by the oestrogen receptor [73] supports our
ﬁndings.
Modelling the initiation and progression of
prostate cancer
The development of transgenic and knockout tech-
nologies has led to the creation of a wide vari-
ety of disease models of human cancers, includ-
ing prostate cancer. Wang et al [74] generated a
PtenloxP/loxP PB–Cre4 mouse model bearing a con-
ditional knockout for tumour suppressor gene PTEN,
which is frequently mutated in human prostate can-
cers. The mouse model recapitulates the disease course
seen in humans, progressing sequentially from hyper-
plasia to PIN, invasive adenocarcinoma and ultimately
to metastasis. Only very recently, the same group
managed to demonstrate the direct involvement of
prostate stem/progenitor cells in this disease process
[75]. Using the same model, they showed that PTEN
suppresses proliferation of basal cells but allows them
to differentiate, whereas PTEN − basal cells undergo
extensive proliferation and ultimately tumour forma-
tion. Introduction of constitutively active AKT in Sca-
1-enriched murine prostate epithelial cells resulted in
the initiation of prostate tumourigenesis, more so than
Sca1− cells [76]. This clearly demonstrates that epithe-
lial stem cells can be a target for prostate tumourige-
nesis and that aberrant activation of the PTEN–AKT
signalling axis may be an initiating event. However,
over-expression of both AR and AKT is sufﬁcient
to induce prostate carcinomas with progression to
androgen-independent disease [77], implying that the
initiating cell does not need to be a stem cell, at least
in this mouse model.
It is clear that without an understanding of the
sequence of genetic alterations leading to prostate can-
cer, these models, although useful, can be misleading.
Thus, the approach taken by Witte and colleagues [76],
to compare the tumourigenic potential of stem and
differentiated cells following perturbation of speciﬁc
pathways is a step forward.
Stem cells and therapy resistance
The goal of existing therapies, such as androgen abla-
tion, has been to eradicate the bulk of cells within a
tumour. However by targeting the AR+ population,
resistance occurs in most patients. Mechanisms such
as AR ampliﬁcation (resulting in increased sensitivity
to androgens) do occur, but the resultant tumour may
well arise from a more primitive AR− clone. Andro-
gen ablation therapy may actually promote disease
progression by activating normally quiescent cancer
stem cells to repopulate the tumour with androgen-
independent cells. We should therefore aim to develop
therapeutics that can selectively target cancer stem
cells, rather than more differentiated cancer cells. By
directing expression analysis to enriched populations
of cancer stem cells, the identiﬁcations of novel ther-
apeutic targets should therefore be more effective
[48].
Normal stem cells from various tissues appear
to be more resistant to chemotherapeutic reagents
than mature cell types [78] and characteristically
express drug-resistance proteins, such as MDRI and
ABC transporters [79,80]. As discussed earlier, stem
cells are quiescent, long-lived cells that are protected
by their niche. This means they are protected both
by location and by their lack of susceptibility to
chemotherapeutic agents that target only proliferating
cells. Indeed, the microenvironment in which stem
cells are situated should not be overlooked and it may
contribute to the success or failure of a treatment.
Radiotherapy and some chemotherapeutic agents
induce DNA damage, resulting in cell death pathways
being activated and tumour cells being successfully
killed. However, efﬁcient DNA repair mechanisms
and active anti-apoptotic pathways, as well as effects
of the cell cycle, can make these treatments inef-
fective. This is a well-established phenomenon and
there is evidence of these features in tumour stem
cells from solid tumours [81–83]. Recently, Bao et al
[81] reported that after irradiation, CD133+ glioma
stem cells showed an increase in DNA damage check-
point activation and more efﬁcient DNA repair, rel-
ative to the CD133− cells. Signiﬁcantly, by inhibit-
ing the checkpoint, using a Chk1/Chk2 inhibitor, this
restored radiosensitivity. This lends support to a two-
pronged cancer therapy approach combining DNA
damaging agents with DNA repair inhibitors [84,85].
In addition, Liu et al [86] showed that CD133+ glioma
cells are more resistant than CD133− cells to sev-
eral chemotherapeutic agents. They showed that this
resistance could be attributed to increases in anti-
apoptotic factors. These studies have been strength-
ened by the ﬁnding that CD133 expression could
be correlated with the outcome of treatment when
analysing gene expression proﬁles of 80 glioblas-
tomas [87]. A study on rhabdoid teratoma tumour cells
demonstrated that the CD133+ cells in this cancer
had increased expression of an anti-apoptotic factor
(bcl-2) and increased expression of proteins involved
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in DNA damage response (phosphorylated ATM and
Rad17) [82]. In hepatocellular carcinoma, CD133+
cells are resistant to doxorubicin and ﬂuorouracil,
and this is attributed to expression of bcl-2, Akt and
PKB, components of an anti-apoptotic survival path-
way [83].
Evidence of the importance of DNA damage
response in prostate cancer has already been provided
from studies in prostate cancer cell lines and prostate
cancer tissues [88]. Examples of this include expres-
sion of activated forms of ATM, Chk2 and p53 in
prostatic intraepithelial neoplasia [89,90]. In fact, this
initial DNA damage response and checkpoint activa-
tion is seen as a cancer-preventative mechanism [91].
This is in line with the ﬁndings that DNA repair,
cell-cycle checkpoints and apoptosis pathways are fre-
quently abrogated in cancer cells, including prostate
cancer cells. For example, defects in mismatch repair
and base excision repair have been reported in prostate
cancer cell lines. [92,93].
There is also evidence that response to double-
strand DNA breaks is altered in prostate cancer cells.
There is an association with prostate cancer risk and
mutations in the BRCA1 and BRCA2 proteins, which
are part of a protein complex that responds to DNA
damage [94]. Also, from studies in prostate cancer cell
lines it was shown that they have different responses
to DNA damage than normal prostate cells. Prostate
cancer cells have defective cell cycle checkpoints
and, although they over-express some DNA damage
response proteins, they paradoxically have defective
DNA repair. A review by Bristow [95] gives a
comprehensive account of the relationship between the
DNA damage response and prostate cancer.
Taken together, these studies suggest that the bulk
of tumour cells may have a defective DNA damage
response, which may make them more susceptible to
some treatments and may have contributed to them
becoming tumourigenic. However, the cancer stem
cells may have enhanced DNA damage response and
are thus resistant to treatment.
Conclusions and future perspectives
The development of more effective treatment strate-
gies for prostate cancer must target all the cells within
a tumour. Gene expression proﬁling from our labo-
ratory has highlighted key cell signalling pathways
that are over-represented in the cancer stem cell pop-
ulation. Abrogation of these pathways, leading to
disruption of self-renewal, should be a key area of
research. More sophisticated modes of therapy may
be necessary, such as combination of a DNA damag-
ing agent with a DNA repair inhibitor. Ultimately, it
would be desirable to have a treatment against prostate
cancer stem cells that could be used in combina-
tion with androgen ablation therapy to reduce tumour
mass.
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